Sullivan & Cromwell

Rachel Yu

Deals
7
Latest
Jul 2026
Most deals in
Biotech

Firm

Deals by year
Rachel Yu: deals by year0720252026 YTD: 4 M&A2026 YTD: 3 Equity raisings72026 YTDM&AEquity raisings

Often works with

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deals Rachel Yu was named on, most recent first
Jul 2026 Avere Therapeutics ––PlacementLegal adviser to Hansoh PharmaAnnounced320.0Biotech+1Avere Therapeutics placement
Jul 2026 Avere Therapeutics –NextCureMergerLegal adviser to Hansoh PharmaAnnounced–Biotech+1NextCure and Avere Therapeutics merger
Jun 2026 Nuvalent –GSKAcquisitionLegal adviser to DeerfieldPending10,600.0Biotech+2GSK acquisition of Nuvalent
Jun 2026 CIBC Caribbean Bank Canadian Imperial Bank of CommerceThe Bank of N.T. Butterfield & SonAcquisitionLegal adviser to Butterfield (acquirer)Announced1,800.0Banking+1The Bank of N.T. Butterfield & Son acquisition of CIBC Caribbean Bank
May 2026 Pershing Square ––IPOLegal adviser to the issuerListed5,000.0Asset & Wealth ManagementPershing Square IPO
May 2026 CSAT Solutions Insight EquityVerdant SolutionsAcquisitionLegal adviser to Verdant Solutions (acquirer)Completed–Business Services+1Verdant Solutions acquisition of CSAT Solutions
Apr 2026 Madison Air Solutions Corp ––IPOLegal adviser to the lead managersListed2,232.7ManufacturingMadison Air Solutions Corp IPO

Deals where Rachel Yu is named on the firm's deal team, by the firm or the press.

Suggest a correction

A missing deal, a wrong firm, a move between firms, or two different people shown as one. A link to a public source helps.